Compare TTGT & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTGT | NGEN |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.8M | 197.5M |
| IPO Year | 2024 | N/A |
| Metric | TTGT | NGEN |
|---|---|---|
| Price | $4.47 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $10.75 | ★ $18.00 |
| AVG Volume (30 Days) | 349.8K | ★ 692.6K |
| Earning Date | 05-07-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $2.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.37 | $1.58 |
| 52 Week High | $7.37 | $5.93 |
| Indicator | TTGT | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.80 | 32.57 |
| Support Level | $3.52 | $1.59 |
| Resistance Level | $4.75 | $2.22 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 83.27 | 2.67 |
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. The company provides marketing and sales services that deliver business impact for enterprise technology companies. It develops editorial content across multiple technology-focused websites and channels to engage audiences researching information technology solutions. The company generates revenue by providing market insight and market access to the technology market, including enterprise technology, artificial intelligence, channel, cybersecurity, media & entertainment, and service providers. Geographically, it derives the majority of revenue from North America.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.